Brain scan study aims to predict glioblastoma drug response
NCT ID NCT04566185
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed pilot study tested whether two types of brain scans—FDG PET and CT perfusion—can predict how well the drug bevacizumab works in people with recurrent glioblastoma, an aggressive brain cancer. Fourteen patients were scanned before treatment and then classified as responders or non-responders based on MRI results. The goal is to find a way to identify who will benefit from this therapy, avoiding unnecessary side effects for those who won't.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bevacizumab (anti-angiogenic therapy)
What this could lead to
If successful, this could help doctors predict which patients with recurrent glioblastoma will respond to bevacizumab, enabling more personalized treatment decisions.
What could go wrong
This is a very small pilot study with only 14 participants, so results may not apply broadly. The scans are being tested as predictors, not as a proven treatment guide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nimes
Nîmes, 30029, France